Reduced-intensity conditioning for acute myeloid leukemia: is this strategy correct

This publication has 56 references indexed in Scilit:

• Do minitransplants have minicosts? A cost comparison between myeloablative and nonmyeloablative allogeneic stem cell transplant in patients with acute myeloid leukemia
  Bone Marrow Transplantation, 2005
• Comorbidity indices in hematopoietic stem cell transplantation: a new report card
  Bone Marrow Transplantation, 2005
• Palifermin for Oral Mucositis after Intensive Therapy for Hematologic Cancers
  New England Journal of Medicine, 2004
• Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning
  Blood, 2004
• Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS
  Blood, 2004
• Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: A phase I study
  Transplantation and Cellular Therapy, 2004
• Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation
  Blood, 2003
• Second EBMT Workshop on reduced intensity allogeneic hemopoietic stem cell transplants (RI-HSCT)
  Bone Marrow Transplantation, 2002
• Successful allogeneic engraftment of mismatched unrelated cord blood following a nonmyeloablative preparative regimen
  Blood, 2001
• Bone Marrow Transplants from Unrelated Donors for Patients with Chronic Myeloid Leukemia
  New England Journal of Medicine, 1998